He Xiao-Jian, Wang Xiao-Ling, Sun Dong-Jie, Huang Xiao-Yan, Liu Gang, Li Da-Zhou, Lin Hai-Lan, Zeng Xiang-Peng, Li Dong-Liang, Wang Wen
Department of Digestive Diseases, Fuzong Clinical Medical College, Fujian Medical University, Fuzhou, China.
Department of Digestive Diseases, 900TH Hospital of Joint Logistics Support Force, Fuzhou, China.
Therap Adv Gastroenterol. 2023 Jan 28;16:17562848221147763. doi: 10.1177/17562848221147763. eCollection 2023.
We previously reported that antofloxacin-based bismuth quadruple therapy was safe and effective for () eradication. It is not clear whether the addition of () to antofloxacin-based quadruple therapy can improve the eradication rate of and reduce adverse events.
To investigate the effect of adding to antofloxacin-based quadruple therapy on the eradication rate of and the adverse events.
Single-center, prospective randomized controlled study.
A total of 172 patients with infection were randomly assigned to the test and control groups. Patients in the control group ( = 86) received antofloxacin-based bismuth quadruple therapy for 14 days. On this basis, cases in the test group ( = 86) received 500 mg b.i.d. The eradication rate of and adverse events were observed 4 weeks after the treatment.
There were no statistically significant differences in the eradication rates of and frequency of diarrhea between the test group and control group ( > 0.05). The duration of diarrhea in the test group was significantly shorter than in the control group ( < 0.001). In addition, the two groups exhibited similar adverse event rates for epigastric pain, abdominal distention, dizzy, vomiting, and rash ( > 0.05). The severity of adverse reactions was similar between the two groups ( > 0.05), and most of them had mild adverse events.
Although the addition of to antofloxacin-based quadruple therapy could not improve the eradication rate of , it could shorten the time of antibiotic-associated diarrhea and reduce the incidence of diarrhea.
ChiCTR2200056931.
我们之前报道过基于安托氟沙星的铋剂四联疗法对（）根除是安全有效的。尚不清楚在基于安托氟沙星的四联疗法中添加（）是否能提高（）的根除率并减少不良事件。
探讨在基于安托氟沙星的四联疗法中添加（）对（）根除率和不良事件的影响。
单中心、前瞻性随机对照研究。
总共172例（）感染患者被随机分配到试验组和对照组。对照组（n = 86）患者接受基于安托氟沙星的铋剂四联疗法14天。在此基础上，试验组（n = 86）患者每日两次口服500mg（）。治疗4周后观察（）的根除率和不良事件。
试验组和对照组在（）根除率和腹泻频率方面无统计学显著差异（P>0.05）。试验组腹泻持续时间明显短于对照组（P<0.001）。此外，两组在上腹疼痛、腹胀、头晕、呕吐和皮疹的不良事件发生率方面相似（P>0.05）。两组不良反应的严重程度相似（P>0.05），且大多数为轻度不良事件。
虽然在基于安托氟沙星的四联疗法中添加（）不能提高（）的根除率，但可缩短抗生素相关性腹泻的时间并降低腹泻发生率。
ChiCTR2200056931。
